All stock lists
Inovio Pharmaceuticals, Inc. (NASDAQ:INO)
US · Delayed Price · Currency is USD
Also listed: GBMB.F, GBM.FHealthcare · Biotechnology
1.89+1.29 (+213.75%)
Market cap
$131M
Insider Score
Health Score
Analyst consensus
Listed since
Dec 8, 1998
Website
Insider Score
––Not scored
INO Insider Score
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
INO analyst forecast
INO analyst consensus
Moderate Buy3 ratings
Buy 3 Hold 0 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
INO 12-month price target
$5.00+151.3% upsideaverage of 1 firm
$5.00High
$5.00Low
INO ratings mix, last 12 months
Buy Hold Sell
Best analysts covering INO
No firm covering INO has enough calls with a finished 1Y holding period to rank yet.
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
INO analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| — | HC Wainwright & Co. | Buy | — | — | Upgraded | 2026-11-02 |
| H.C. Wainwright | — | $5.00 | +186.9% | — | 2026-11-02 | |
| — | Jefferies | Buy | — | — | Upgraded | 2026-08-13 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2026-08-03 |
| — | HC Wainwright & Co. | Neutral | — | — | Reiterated | 2026-06-01 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2025-11-14 |
| — | HC Wainwright & Co. | Neutral | — | — | Reiterated | 2025-08-14 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2025-05-14 |
| — | RBC Capital | Sector Perform | — | — | Reiterated | 2025-05-14 |
| — | HC Wainwright & Co. | Neutral | — | — | Reiterated | 2025-03-19 |
| — | RBC Capital | Sector Perform | — | — | Reiterated | 2025-03-19 |
| — | HC Wainwright & Co. | Neutral | — | — | Reiterated | 2025-01-13 |
| — | JMP Securities | Market Outperform | — | — | Reiterated | 2025-01-10 |
| — | HC Wainwright & Co. | Neutral | — | — | Reiterated | 2024-11-18 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2024-11-18 |
| — | RBC Capital | Sector Perform | — | — | Reiterated | 2024-11-15 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2024-08-12 |
| — | RBC Capital | Sector Perform | — | — | Reiterated | 2024-08-09 |
| — | HC Wainwright & Co. | Neutral | — | — | Reiterated | 2024-07-15 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2024-03-08 |
| — | RBC Capital | Sector Perform | — | — | Reiterated | 2024-03-07 |
| — | Oppenheimer | Outperform | — | — | Upgraded | 2024-01-25 |
| — | RBC Capital | Perform | — | — | Reiterated | 2023-05-11 |
| — | RBC Capital | Sector Perform | — | — | Reiterated | 2023-05-10 |
| — | RBC Capital | Sector Perform | — | — | Reiterated | 2023-03-01 |
| — | Maxim Group | Hold | — | — | Downgraded | 2022-11-08 |
| — | B of A Securities | Underperform | — | — | Downgraded | 2022-10-31 |
| — | RBC Capital | Sector Perform | — | — | Reiterated | 2022-08-09 |
| — | Oppenheimer | Perform | — | — | Downgraded | 2022-05-10 |
| — | RBC Capital | Sector Perform | — | — | Reiterated | 2022-03-01 |
| — | B of A Securities | Neutral | — | — | Upgraded | 2022-01-20 |
| — | RBC Capital | Sector Perform | — | — | Reiterated | 2021-10-31 |
| — | B of A Securities | Underperform | — | — | Downgraded | 2021-09-09 |
| — | Jefferies | Hold | — | — | Reiterated | 2021-06-24 |
| — | B of A Securities | Neutral | — | — | Reiterated | 2021-03-23 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2021-02-12 |
| — | Roth Capital | Sell | — | — | Downgraded | 2020-11-16 |
| — | Roth Capital | Neutral | — | — | Upgraded | 2020-11-09 |
| — | Cantor Fitzgerald | Neutral | — | — | Downgraded | 2020-09-27 |
| — | Maxim Group | Buy | — | — | Upgraded | 2020-09-27 |
| — | Maxim Group | Hold | — | — | Downgraded | 2020-06-30 |
| — | HC Wainwright & Co. | Neutral | — | — | Downgraded | 2020-06-28 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2020-06-25 |
| — | Stifel | Hold | — | — | Downgraded | 2020-06-25 |
| — | Benchmark | Buy | — | — | Reiterated | 2020-05-21 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2020-04-29 |
| — | Stifel | Buy | — | — | Reiterated | 2020-04-28 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2020-04-14 |
| — | Piper Sandler | Neutral | — | — | Downgraded | 2020-03-12 |
| — | PiperJaffray | Overweight | — | — | Reiterated | 2020-01-03 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2020-01-02 |
| — | Roth Capital | Buy | — | — | Reiterated | 2019-12-19 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2019-03-26 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2017-10-18 |
| — | PiperJaffray | Overweight | — | — | Upgraded | 2017-06-08 |
| — | Piper Sandler | Overweight | — | — | Upgraded | 2017-06-07 |
| — | PiperJaffray | Neutral | — | — | Downgraded | 2017-03-16 |
| — | Piper Sandler | Neutral | — | — | Downgraded | 2017-03-15 |
| — | Aegis Capital | Buy | — | — | Reiterated | 2016-11-07 |
| — | Maxim Group | Hold | — | — | Downgraded | 2016-08-08 |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.